Evidence map›Paper›PMID 33547213›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.

Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Prospective pilot study with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. A high-affinity CEA-targeted nanobody forJournal of nanobiotechnology · 2025
    Article
  3. Nuclear Imaging of Bispecific Antibodies on the Rise.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Review
  4. Review
  5. Pretargeting: A Path Forward for Radioimmunotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Caroline Bodet-MilinUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France; caroline.milin@chu-nantes.fr.
Alain Faivre-ChauvetUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Thomas CarlierUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Catherine AnsquerUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Aurore RauscherPharmacy Unit, ICO Cancer Center, Saint-Herblain, France.
Eric FrampasUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Frederique ToulgoatRadiology Department, University Hospital, Nantes, France.
Damien MassonBiology Department, University Hospital, Nantes, France.
Mickael BourgeoisUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Evelyne CeratoDélégation à la Recherche Clinique et à l'Innovation, University Hospital, Nantes, France.
Vincent RohmerEndocrinology Department, University Hospital, Angers, France.
Olivier CouturierNuclear Medicine Department, University Hospital, Angers, France.
Delphine DruiEndocrinology Department, University Hospital, Nantes, France.
David M GoldenbergIBC Pharmaceuticals, Inc., Morris Plains, New Jersey.
Robert M SharkeyImmunomedics, Inc., Morris Plains, New Jersey; and.
Jacques BarbetGIP Arronax, Saint-Herblain, France.
Francoise Kraeber-BodereUniversité de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Nantes Université · FRCentre National de la Recherche Scientifique · FRInserm · FRInstitut Génétique Nantes Atlantique · FRUniversité d'Angers · FRCentre d'Investigation Clinique de Nantes · FRCentre Hospitalier Universitaire de Nantes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the

Indexed as

Carcinoembryonic AntigenDihydroxyphenylalanineNeoplasm MetastasisPositron Emission Tomography Computed TomographyThyroid NeoplasmsAdultAgedCarcinoma, NeuroendocrineFemaleHumansMaleMiddle AgedRecurrenceSensitivity and SpecificityCarcinoembryonic AntigenDihydroxyphenylalaninefluorodopa F 18bispecific antibodycarcinoembryonic antigenimmuno-PETMTCpretargeted radioimmunoimaging

Identifiers

PMID33547213
PMCPMC8882894
OpenAlexW3128555591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.